VisionGate’s quick, non-intrusive lung cancer test based on 3D cellular imaging helps detect early lung cancer when the chance of cure is the strongest.

VisionGate Leading Research Against Lung Cancer

At the Forefront of Novel Science

VisionGate is a biotechnology company leading the battle against lung cancer in high-risk patients using simple non-invasive testing, 3D cell imaging, and a patented AI-powered cancer detection process.

Our Breakthrough
Technology

VisionGate’s quick, non-intrusive lung cancer test based on 3D cellular imaging helps detect early lung cancer when the chance of cure is the strongest.

Non-Intrusive
Testing

Sputum (phlegm) samples from a deep cough (LuCED° Lung Test) are collected over a three-day period using a take-home test kit.

AI-Powered
Cancer Detection

Our AI-based classification of cells can identify 1,000 cell images per second and over 800 3D cell features at a 200 nanometer isotropic resolution.

Patented Cell-CT Imaging

High-resolution 3D images (Cell-CT™) of individual cells contained in the sputum measure hundreds of disease indicators and molecular markers in each cell.

VisionGate
Potential

VisionGate’s intellectual property portfolio has comprised over 35 issued patents and 5 patents pending.

For investment opportunities, please contact us to receive our informational memorandum.

visiongate potentional 35 patents 51 billion

Our Clinical Partners

Feinber School of Medicine
northwestern university feinberg school of medicine logo